Download
conservative management of chronic renal failure n.
Skip this Video
Loading SlideShow in 5 Seconds..
Conservative Management of Chronic Renal Failure PowerPoint Presentation
Download Presentation
Conservative Management of Chronic Renal Failure

Conservative Management of Chronic Renal Failure

185 Views Download Presentation
Download Presentation

Conservative Management of Chronic Renal Failure

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Conservative Management of Chronic Renal Failure Dr. Sham Sunder

  2. Definition – CKD • Kidney damage for >= 3months , as defined by structural / functional abnormalities of kidney with or without decreased GFR, and manifest by either : • Pathologic abnormalities • Markers of kidney damage, including abnormalities in composition of blood / urine or abnormalities on imaging • GFR < 60 ml/min/1.73m2 for >=3 months, with / without kidney damage

  3. Pathologic Abnormalities : • By Radiology – USG / CT / MRI etc… • By Histology – Renal Biopsy

  4. Markers of kidney damage : • Microalbuminuria • Proteinuria • Hematuria esp associated with proteinuria • Casts ( with cellular elements )

  5. GFR Estimating Equations Cockcroft-Gault formula Ccr (ml/min) = (140-age) x weight *0.85 if female 72 x Scr MDRD Study equation GFR (ml/min/1.73 m2) = 186 x (Scr)-1.154 x (age)-.203 x (0.742 if female) x (1.210 if African American)

  6. NKF – K/DOQI Stages of CKD

  7. Action Plan according to CKD - Stage

  8. Conservative Management • Diagnosis • Measures to slow progression • Estimate Progression • Evaluation and Treatment of Complications • Preparation for Renal Replacement Therapy

  9. Diagnosis • History • Physical Examination

  10. Tests & Diagnostics

  11. Slowing the Progession of CKD

  12. Protein Restriction • Reducing Intraglomerular Hypertension • Reducing Proteinuria • Control of Blood Glucose • Control of Blood Pressure

  13. Protein Restriction • Reduces symptoms associated with uremia • Slows the rate of decline in renal function at earlier stages of renal diseases • K/DOQI clinical practice guidelines recommend daily protein intake between 0.60 – 0.75 g / Kg per day • 50 % of protein intake should be of high biological value • As patient approaches CKD Stage V, spontaneous protein intake decreases & patient enter a state of Protein – Energy Malnutrition . Recommended protein intake is 0.9 g / Kg per day

  14. Reducing Intraglomerular Hypertension & Proteinuria • Increased intraglomerular filtration pressure & glomerular hypertrophy - a response to loss of nephron number • It promotes ongoing decline of kidney function even if the inciting process has been treated. • ACEI & ARBs • Inhibit angiotensin induced vasoconstriction of efferent arteriole • Reduces intraglomerular filtration pressure and proteinuria

  15. If monotherapy is not effective , combined therapy with both ACEI & ARB can be tried • 2nd line drugs : Calcium Channel Blockers Diltiazem , Verapamil • Especially - Diabetic Nephropathy & Glomerular diseases

  16. Slowing Progression of Diabetic Renal Disease • Leading cause of Chronic Kidney Disease • Control of Blood Glucose : excellent glycemic control reduces the risk of kidney disease & its progression in both Type 1 & 2 Diabetes Mellitus • Recommendations : FBS : 90 – 130 mg/dl HbA1C < 7% • Control of Blood Pressure & Proteinuria : ACEI & ARBs

  17. Control of Blood Pressure • Hypertension : sodium and water retention reninangiotensin system activation • Control of BP : to slow progression of CKD to prevent extrarenal complications ( cardiovascular disease / stroke ) • Goal : BP < 130 / 80 mm Hg BP < 125 / 75 mm Hg ( DM / Proteinuria > 1g/day )

  18. Salt Restriction • Diuretics • Loop Diuretics : Furosemide 40 mg BD Bumetanide 1mg BD • Thiazides : less efficacious gfr < 30 – 40 ml/min • Both ameliorate hyperkalemia seen with ACEI / ARB • ACEI / ARB • Check S.Creat & S.K+ within 1 -2 weeks • Upto 30 % increase in creatinine is acceptable • Beta blockers / CCB / Alpha blockers / Vasodilators

  19. Estimate Progression

  20. Evaluation & Treatment of Complications

  21. Anemia • Bone Disorders • Dyslipidemia • Cardiovascular disease

  22. Anemia • Defined as Hemoglobin < 13.5 g/dl in males < 12 g/dl in females • Normocyticnormochromic anemia – as early as in Stage III CKD or universally by Stage IV CKD • Primary cause : insufficient production of Erythropoetin • Additional factors : iron deficiency folate / vit B12 deficiency chronic inflammation hyperparathyroidism / bm fibrosis

  23. Anemia - goals • Target Hb : 11 g/dl • Target Iron status : TSAT : lower limit > = 20 S.Ferritin : ng/ml lower limit : 200 – HD CKD 100 – Non HD CKD > 500 not routinely recommended • Check Hb monthly while on ESAs • Iron studies monthly when started on ESA • On stable ESA Therapy : Iron studies can be done 3 monthly

  24. Anemia – treatment options • Ferrous sulphate 325 mg bid – tid • IV Iron Dextran • IV Iron Sucrose • IV Sodium Ferric Gluconate Complex • Folic acid and Vitamin B 12 supplements • Erythropoetin Stimulating Agents : Epoetinalfa Epoetin beta Darbepoetinalfa • Epoetinalfa / beta : 50 -100 IU / Kg SC per week • Darbepoetinalfa : 40 mcg SC every 2 weeks

  25. Bone Disorders Causative factors • Osteitis Fibrosa Cystica • Osteomalacia • Adynamic bone disease • Mixed osteodystrophy • Secondary Hyperparathyroidism • Vitamin D deficiency • Acidosis • Aluminium accumulation • Osteoporosis in elderly • Osteopenia caused by steroids

  26. Renal bone disease – significantly increase mortality in CKD patients • Hyperphosphatemia – one of the most important risk factors associated with cardiovascular disease in CKD patients

  27. Treatment goals • K/DOQI recommends : • CKD Stage III & IV : S.Phosphorus : 2.7 - 4.6 mg / dl • CKD Stage V : S.Phosphorus : 3.5 - 5.5 mg / dl

  28. Frequency of testing

  29. Treatment • Reduce dietary phosphate intake • Phosphate binders : calcium carbonate calcium acetate aluminium hydroxide magnesium carbonate ( rarely used ) sevelamer hydrochloride lanthanum carbonate • The use of calcium salts is limited by development of hypercalcemia • Calcium acetate poses a less problem as less calcium is absorbed

  30. Treatment • Calcimimetics – Cinacalcit : • Agent that increase calcium sensitivity of the calcium sensing receptor expressed by parathyroid gland • Down regulating the parathyroid hormone secretion • Reduce hyperplasia of parathyroid gland • Calcitriol 0.25 mcg OD • Paricalcitol 1 mcg daily or 2mcg 3 times a week

  31. Vitamin D deficiency : • < 5 ng/ml – Ergocalciferol 50000 IU orally weekly for 12 weeks and then monthly thereafter • 5 – 15 ng/ml – Ergocalciferol50000 IU orally weekly for 4 weeks and then monthly thereafter • 16 – 30 ng/ml – Monthly Ergocalciferol • Acidosis : K/DOQI – total Co2 >=22 mEq/L Sodium bicarbonate 650 – 1300 mg bid – tid

  32. Dyslipidemia • A major risk factor for cardiovascular morbidity & mortality • Prevalence of hyperlipidemia increases as renal functions diminish • All patients with CKD must be evaluated for Dyslipidemia • Fasting lipid profile – annually

  33. Dyslipidemia • Stage V CKD patients with dyslipidemia should always be evaluated for secondary causes : • Nephrotic syndrome • Hypothyroidism • Diabetes mellitus • Excessive alcohol consumption • Liver disease • Drugs : oral contraceptives , haart etc… • Goal : LDL – Cholesterol < 100 mg / dl

  34. Dyslipidemia • LDL : 100 – 129 mg/dl : Lifestyle changes Not responded : Low dose statin • LDL >= 130 mg/dl : Lifestyle changes + Statins • TG >= 200 mg/dl : Lifestyle changes + Statins

  35. Cardiovascular Disease

  36. Treatment • Control BP : ACEI / ARB • Treat dyslipidemia : Lifestyle changes + Statins • Good Glycemic control • Treat anemia • Correct hyperphosphatemia • Treat hyperparathyroidism • Correct hyperkalemia

  37. Immunization • Hepatitis B vaccination : 3 doses (0,1,2 months ) higher dose ( 40 mcg / ml ) • Pneumococcal vaccination : single dose one time revaccination 5 yrs after initial vaccination • Influenza vaccination : recommended annually for adults > 50 yrs age

  38. Preparation for Renal Replacement Therapy • Patients of CKD Stage IV approaching Stage V should be referred for • Vascular access if hemodialysis is preferred • Peritoneal dialysis catheter placement if peritoneal dialysis is preferred • AVF is most preferred access for HD patients • Ideally created 6 months prior to start of HD • Non dominant upper extremity • And that arm is to be preserved – no iv lines • AVG : 3-6 weeks prior to start of HD • PD Catheter : 2 weeks prior to start of HD

  39. Look for reversibility !

  40. Mangement for CKD patients according to Stage

  41. GFR not below 15 ml/min.1.73m2 but in presence of • Intractable volume overload • Hyperkalemia • Hyperphosphatemia • Hypercalcemia / Hypocalcemia • Metabolic acidosis • Anemia • Uremic encephalopathy • Uremic pericarditis • Severe hypertension , acute pulmonary edema

  42. Thank You !